Cellebrite DI (NASDAQ:CLBT) Earns Buy Rating from Analysts at DA Davidson

Posted by Geri Gentry on May 27th, 2026

Research analysts at DA Davidson initiated coverage on shares of Cellebrite DI (NASDAQ:CLBT – Get Free Report) in a note issued to investors on Wednesday, Marketbeat.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. DA Davidson’s price objective would suggest a potential upside of 54.14% from the stock’s previous close.

A number of other brokerages have also weighed in on CLBT. Needham & Company LLC cut their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Get Our Latest Research Report on Cellebrite DI

Cellebrite DI Stock Performance

Shares of CLBT traded up $0.09 during mid-day trading on Wednesday, reaching $12.98. The company had a trading volume of 226,711 shares, compared to its average volume of 1,902,542. The company’s 50 day simple moving average is $13.33 and its 200 day simple moving average is $15.33. Cellebrite DI has a 1-year low of $11.02 and a 1-year high of $19.98. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of 46.22, a P/E/G ratio of 1.58 and a beta of 1.15.

Insider Buying and Selling

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares in the company, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 13,269 shares of company stock worth $169,592 over the last ninety days. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Cellebrite DI

Several hedge funds have recently modified their holdings of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares in the last quarter. Advisory Services Network LLC acquired a new position in shares of Cellebrite DI during the third quarter valued at about $40,000. CWM LLC boosted its position in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 889 shares in the last quarter. First Horizon Corp boosted its position in shares of Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after purchasing an additional 2,337 shares in the last quarter. Finally, Vestcor Inc acquired a new stake in shares of Cellebrite DI in the 3rd quarter valued at about $70,000. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

(Get Free Report)

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.